Dyne Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero and one of the biotechnology analysts here at JPMorgan. Our next presenting company is Dyan therapeutics and speaking, on behalf of the Company, we have CEO, Josh Brumm. Josh, over to you.
Thanks, Tom, and good afternoon, everybody. It's great to be here. Thank you to Morgan Stanley for the invite and thank you for all attending a pretty exciting story for us to tell here kicking off the year.I'll start with forward-looking statements we may make today. Please see our SEC filings for more information on those matters.
Ultimately, what I want to do is just give a very brief overview introduction and Willdan is going to come up and as you may know, we put out some data, so proof-of-concept data clinically in both Tier one and in our DMD program last week. And once we have enough representation of that of that data. So we're looking forward to it. I wanted to start by just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |